Nautilus Biotechnology, Inc.

Nautilus Biotechnology (NAUT) reported zero cyber incidents and zero red-flag 8-K filings in the past 90 days, suggesting operational stability in the near term. However, a quiet recent period does not rule out structural risks—the company operates in a capital-intensive biotech sector where financing history and shareholder dilution patterns often determine long-term outcomes. The full $49 Report extends the analysis window to 12 months, calculates dilution risk scores, maps financing rounds and their terms, and flags AI-detected anomalies in officer changes and forward guidance. This deeper view reveals the cash runway and equity pressure points that surface-level filings may obscure.